Emb-06 is a tetravalent CD3 × BCMA bispecific antibody in a Fabs-In-Tandem-Ig format with four active antigen-binding sites. It targets BCMA on tumor cells and CD3 on T cells, promoting immune activation and antitumor activity. M.W 241.36 kDa.

Yh32367 is a humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9). It exhibits potential immunostimulating and antineoplastic activities. M.W 200.52 kDa.

Ngm707 is a humanized monoclonal antibody that dual antagonizes ILT2 and ILT4, key inhibitory immune checkpoint receptors. It has potential immunomodulatory and antitumor effects, used alone or in combination for advanced solid tumors. M.W 148.32 kDa.

Gen3009 is a bispecific IgG1 antibody targeting two non-overlapping epitopes on CD37 (biparatopic) with an E430G hexamerization-enhancing mutation. It exhibits significant anti-tumor efficacy in vivo in human cell line- and patient-derived xenograft models, with the potential to treat human B-cell malignancies. MW: 145.37 KD.

Gen1044 is an anti-CD3/anti-5T4 bispecific antibody, targeting both the human T-cell surface antigen CD3 and oncofetal antigen 5T4, with potential immunomodulating, antineoplastic and antitumor activities. MW: 145.22 kDa.

Regn7075 is a first-in-class costimulatory bispecific antibody (bsAb), aims to restore immune sensitivity in traditionally non-immunoresponsive tumors by bridging CD28+ T cells with EGFR-expressing tumor cells. It can enhance immune response and anti-tumor immunity. M.W 145.24 kDa.

Hpn536 is a tri-specific, T-cell–activating protein-based construct that binds to mesothelin (MSLN)-expressing tumor cells and CD3ϵ on T cells, leading to T-cell activation and potent redirected target cell lysis. It also binds to serum albumin, extending its plasma half-life. HPN536 demonstrates extended half-life in nonhuman primates (NHP) and has the potential to treat mesothelin-expressing solid […]

Gen1042 is a bispecific antibody that targets and conditional stimulates CD40 and 4-1BB to enhance the priming and reactivation of tumor-specific immunity in patients with cancer. It enhances antitumor immunity by modulating DC and T-cell functions and exhibits biological activity in patients with advanced solid tumors. MW: 145.37 KD.

RO7122290 is a bispecific antibody-like fusion protein consisting of a trimeric ligand for the T-cell co-stimulatory immune receptor 4-1BB (CD137) and an antigen-binding fragment (Fab) moiety targeting the tumor-associated protein fibroblast activation protein (FAP), with potential immunomodulating and antineoplastic activities. It exhibits potential for treating advanced solid tumors. MW: 177.78 KD.

Emb01 is a tetravalent, bispecific antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (cMET) on tumor cells, preventing receptor activation and inducing receptor endocytosis, which effectively eliminates these targets on tumor cell surfaces. It demonstrates significant anti-tumor activity in patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models, […]